ME00199B - Gastrorezistentne farmaceutske formulacije koje sadrže rifaksimin - Google Patents

Gastrorezistentne farmaceutske formulacije koje sadrže rifaksimin

Info

Publication number
ME00199B
ME00199B MEP-2008-311A MEP2008311A ME00199B ME 00199 B ME00199 B ME 00199B ME P2008311 A MEP2008311 A ME P2008311A ME 00199 B ME00199 B ME 00199B
Authority
ME
Montenegro
Prior art keywords
pharmaceutical formulations
formulations containing
containing rifaximin
values
disease
Prior art date
Application number
MEP-2008-311A
Other languages
English (en)
French (fr)
Inventor
Giuseppe C Viscomi
Ernesto Palazzini
Villiam Zamboni
Maria Rosaria Pantaleo
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of ME00199B publication Critical patent/ME00199B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Cilj pedmetnog pronalaska je da obezbedi farmaceutske formulacije koje sadrže rifaksimin u obliku mikrogranula koje su učinjene gastrorezistentnim pomoću polimera koji je nerastvoran pri pH vrednostima između 1,5 i 4,0, a koji se rastvara pri pH vrednosti između 5,0 i 7,5; da obezbedi pripremanje i upotrebu ovih formulacija u proizvodnji medicinskih preparata koji su korisni u tretmanu inflamatome bolesti creva (IBC), posebno Hronove bolesti. Cilj pedmetnog pronalaska je da obezbedi farmaceutske formulacije koje sadrže rifaksimin u obliku mikrogranula koje su učinjene gastrorezistentnim pomoću polimera koji je nerastvoran pri pH vrednostima između 1,5 i 4,0, a koji se rastvara pri pH vrednosti između 5,0 i 7,5; da obezbedi pripremanje i upotrebu ovih formulacija u proizvodnji medicinskih preparata koji su korisni u tretmanu inflamatome bolesti creva (IBC), posebno Hronove bolesti.
MEP-2008-311A 2005-03-07 2006-03-06 Gastrorezistentne farmaceutske formulacije koje sadrže rifaksimin ME00199B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000123A ITBO20050123A1 (it) 2005-03-07 2005-03-07 Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
PCT/EP2006/002022 WO2006094737A2 (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin

Publications (1)

Publication Number Publication Date
ME00199B true ME00199B (me) 2011-02-10

Family

ID=36694343

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2008-311A ME00199B (me) 2005-03-07 2006-03-06 Gastrorezistentne farmaceutske formulacije koje sadrže rifaksimin
MEP-311/08A MEP31108A (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-311/08A MEP31108A (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin

Country Status (30)

Country Link
US (5) US8568782B2 (me)
EP (1) EP1874273B1 (me)
JP (1) JP4827915B2 (me)
KR (1) KR101157220B1 (me)
CN (1) CN101137350B (me)
AU (1) AU2006222206B2 (me)
BR (1) BRPI0608853B8 (me)
CA (1) CA2595033C (me)
CY (1) CY1114132T1 (me)
DK (1) DK1874273T3 (me)
ES (1) ES2398564T3 (me)
HK (1) HK1115801A1 (me)
HR (1) HRP20070432B1 (me)
IL (1) IL184695A (me)
IT (1) ITBO20050123A1 (me)
MA (1) MA29346B1 (me)
MD (1) MD4180C1 (me)
ME (2) ME00199B (me)
MX (1) MX2007010889A (me)
NO (1) NO340155B1 (me)
NZ (1) NZ556740A (me)
PL (1) PL1874273T3 (me)
PT (1) PT1874273E (me)
RS (1) RS52891B (me)
RU (1) RU2403015C2 (me)
SI (1) SI1874273T1 (me)
TN (1) TNSN07290A1 (me)
UA (1) UA90881C2 (me)
WO (1) WO2006094737A2 (me)
ZA (1) ZA200707396B (me)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
ES2905795T3 (es) * 2007-07-06 2022-04-12 Lupin Ltd Composiciones farmacéuticas de rifaximina
US8974825B2 (en) * 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
UA101829C2 (uk) 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ В ТЕРАПЕВТИЧНІЙ ПРАКТИЦІ
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EP2252148B1 (en) * 2008-02-26 2019-03-20 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
EP2475392A4 (en) 2009-09-13 2013-01-09 Salix Pharmaceuticals Ltd METHOD FOR TREATING IRRITATION SYNDROME
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
IT1398550B1 (it) * 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
JP6092629B2 (ja) 2010-03-10 2017-03-08 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミン使用準備済懸濁液
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
EP2593463B1 (en) 2010-07-12 2020-05-06 Salix Pharmaceuticals, Inc. Formulations of rifaximin and uses thereof
JP2013537182A (ja) * 2010-09-13 2013-09-30 シプラ・リミテッド 医薬組成物
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
CN103501767A (zh) * 2011-06-17 2014-01-08 赢创罗姆有限公司 适合于药物或营养制品剂型的包衣组合物
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014015192A1 (en) * 2012-07-18 2014-01-23 Martello Jeannette Time indicator tampon
DE102012024434A1 (de) * 2012-12-14 2014-06-18 Regalismons S.A. Verstärkung der entschäumenden Wirkung von Polysiloxanen, zugehöriger Zusammensetzungen und Lösungen
NZ713440A (en) * 2013-04-12 2019-02-22 Alfasigma Spa Nsaid administration and related compositions, methods and systems.
CN103340856A (zh) * 2013-07-09 2013-10-09 荣港生技医药科技（北京）有限公司 一种利福昔明药物组合物及其制备方法
UA122389C2 (uk) 2014-02-13 2020-11-10 Інсайт Корпорейшн Циклопропіламіни як інгібітори lsd1
ME03654B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
US9474699B2 (en) * 2014-03-31 2016-10-25 Johnson & Johnson Consumer Inc. Compostions and methods for enhancing the topical application of a basic benefit agent
PL3546464T3 (pl) 2014-05-12 2020-11-02 Alfasigma S.P.A. Sposób wytwarzania i zastosowanie postaci krystalicznej Tau rifaksyminy solwatowanej z DEGME
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
ES2757948T3 (es) 2015-04-03 2020-04-30 Incyte Corp Compuestos heterocíclicos como inhibidores LSD1
JP7427363B2 (ja) 2015-08-12 2024-02-05 インサイト・ホールディングス・コーポレイション Ｌｓｄ１阻害剤の塩
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
HUE056045T2 (hu) * 2016-03-24 2022-01-28 Sandoz Ag Rifaximin alfa és delta tartalmú gyógyászati készítmény
AU2017237469B2 (en) * 2016-03-24 2018-06-28 Sandoz Ag Storage stable composition comprising rifaximin alpha
CN110072525B (zh) 2016-09-30 2022-12-02 萨利克斯药品公司 利福昔明的固态分散形式
PL3416627T3 (pl) 2017-04-26 2020-06-01 Sandoz Ag Doustna postać dawkowania zawierająca rifaksyminę w postaci beta
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020208140A1 (en) 2019-04-12 2020-10-15 Sandoz Ag Rifaximin-containing granules
JP2022548788A (ja) * 2019-09-24 2022-11-21 バウシュ ヘルス アイルランド リミテッド リファキシミン液体製剤
JP2023531268A (ja) * 2020-06-26 2023-07-21 バウシュ ヘルス アイルランド リミテッド 標的化放出リファキシミン組成物
CN118922193A (zh) 2022-02-17 2024-11-08 悟而喜制药公司 具有离子交换树脂的法舒地尔口服制剂
MX2024009983A (es) 2022-02-17 2024-08-26 Woolsey Pharmaceuticals Inc Formulaciones orales de fasudil que enmascaran el sabor.

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE751182A (fr) 1969-05-30 1970-11-03 Takeda Chemical Industries Ltd Procede de fabrication d'antibiotiques
US4206677A (en) 1978-07-17 1980-06-10 Teledyne Industries, Inc. Pedal actuator for electronic player piano
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) * 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB2253346A (en) * 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
IT1245907B (it) 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US5549911A (en) * 1994-01-14 1996-08-27 Laboratoires Des Produits Ethiques Ethypharm Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract
US5592021A (en) * 1995-04-26 1997-01-07 Martin Marietta Corporation Clamp for securing a power device to a heatsink
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
DK0935417T3 (da) 1996-10-16 2009-08-10 Napo Pharmaceuticals Inc Enteroformuleringer af proanthocyanidin-polymer-sammensætninger mod diarré
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20030157174A1 (en) * 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
PL361452A1 (en) * 2001-07-27 2004-10-04 Yamanouchi Pharmaceutical Co.Ltd. Compositions containing sustained-release fine grains for tablets quickly disintegrable in the oral cavity and process for producing the same
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ATE482694T1 (de) * 2002-07-05 2010-10-15 Temrel Ltd Zusammensetzung zur kontrollierten wirkstoffabgabe
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
KR20070053221A (ko) 2004-07-16 2007-05-23 씨아이피엘에이 엘티디. 항-히스타민성 조성물
US20060210483A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210492A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CN101594885B (zh) 2006-03-09 2017-07-18 萨利克斯药品公司 利福昔明抗直肠功能障碍制剂
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
ES2660551T3 (es) 2006-05-01 2018-03-22 Napo Pharmaceuticals, Inc. Composiciones y métodos para tratar o prevenir cáncer de colon
PT2054066E (pt) 2006-08-02 2015-07-16 Salix Pharmaceuticals Inc Métodos para tratamento de enterite por radiação
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US8974825B2 (en) 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
ES2905795T3 (es) 2007-07-06 2022-04-12 Lupin Ltd Composiciones farmacéuticas de rifaximina
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
MX2010004333A (es) 2007-10-17 2010-11-30 Salix Pharmaceuticals Ltd Blancos terapeuticos novedosos en enfermedad intestinal.
EP2252148B1 (en) 2008-02-26 2019-03-20 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome
WO2009137672A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
RU2011116400A (ru) 2008-09-26 2012-11-10 Аска Фармасьютикал Ко., Лтд. (Jp) Средство для предотвращения и/или лечения функционального расстройства желудочно-кишечного тракта
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
US20110294726A1 (en) 2009-02-11 2011-12-01 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2442803A4 (en) 2009-06-15 2012-11-28 Salix Pharmaceuticals Ltd MODULATION OF SYSTEMIC EXPOSURE TO RIFAXIMINE
EP2475392A4 (en) 2009-09-13 2013-01-09 Salix Pharmaceuticals Ltd METHOD FOR TREATING IRRITATION SYNDROME
JP2013508428A (ja) 2009-10-26 2013-03-07 トーマス・ジュリアス・ボロディ 新規な腸の併用療法
CN113274355B (zh) 2009-10-27 2023-05-30 鲁平有限公司 利福昔明固体分散体
MX2012005882A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion en espuma topica.
RU2012126084A (ru) 2009-11-23 2013-12-27 Сипла Лимитед Пенная композиция для местного применения
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
EP3650022A1 (en) 2010-02-18 2020-05-13 Salix Pharmaceuticals, Ltd. Methods for treating rifampin resistant clostridium difficilis infections
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
JP6092629B2 (ja) 2010-03-10 2017-03-08 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミン使用準備済懸濁液
EP2593463B1 (en) 2010-07-12 2020-05-06 Salix Pharmaceuticals, Inc. Formulations of rifaximin and uses thereof
JP2013537182A (ja) 2010-09-13 2013-09-30 シプラ・リミテッド 医薬組成物
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
PL2773205T3 (pl) 2011-11-02 2024-09-02 Salix Pharmaceuticals, Inc. Ryfaksymina w leczeniu ustępującej biegunki z przewagą zespołu jelita drażliwego
EP2997034A4 (en) 2013-05-17 2016-12-28 Salix Pharmaceuticals Inc METHODS OF USING RIFAXIMINE IN POSITRON EMISSION TOMOGRAPHY SCANNING (PET)

Also Published As

Publication number Publication date
JP4827915B2 (ja) 2011-11-30
HRP20070432B1 (hr) 2015-02-13
US20140186450A1 (en) 2014-07-03
KR101157220B1 (ko) 2012-07-09
CA2595033C (en) 2013-05-28
WO2006094737A2 (en) 2006-09-14
ITBO20050123A1 (it) 2005-06-06
EP1874273A2 (en) 2008-01-09
MD4180C1 (ro) 2013-03-31
EP1874273B1 (en) 2013-01-02
UA90881C2 (uk) 2010-06-10
TNSN07290A1 (en) 2008-12-31
ES2398564T3 (es) 2013-03-20
NO340155B1 (no) 2017-03-13
BRPI0608853B1 (pt) 2020-05-19
CN101137350B (zh) 2013-09-11
NZ556740A (en) 2010-07-30
BRPI0608853B8 (pt) 2021-05-25
IL184695A (en) 2012-12-31
WO2006094737A3 (en) 2007-02-15
AU2006222206B2 (en) 2010-07-08
MA29346B1 (fr) 2008-03-03
KR20070117616A (ko) 2007-12-12
US8568782B2 (en) 2013-10-29
CN101137350A (zh) 2008-03-05
RU2403015C2 (ru) 2010-11-10
RS52891B (en) 2014-02-28
MEP31108A (en) 2010-10-10
US10285944B2 (en) 2019-05-14
NO20075046L (no) 2007-12-05
PL1874273T3 (pl) 2013-04-30
IL184695A0 (en) 2007-12-03
US20090011020A1 (en) 2009-01-08
SI1874273T1 (sl) 2013-04-30
BRPI0608853A2 (pt) 2010-02-02
US20100330129A1 (en) 2010-12-30
US20200000726A1 (en) 2020-01-02
ZA200707396B (en) 2009-08-26
CY1114132T1 (el) 2016-07-27
HRP20070432A2 (en) 2007-11-30
PT1874273E (pt) 2013-03-11
MD4180B2 (en) 2012-08-31
AU2006222206A1 (en) 2006-09-14
WO2006094737A8 (en) 2007-11-15
BRPI0608853A8 (pt) 2017-12-26
RU2007136428A (ru) 2009-04-20
DK1874273T3 (da) 2013-01-28
MD20070267A (en) 2008-06-30
JP2008531743A (ja) 2008-08-14
HK1115801A1 (en) 2008-12-12
CA2595033A1 (en) 2006-09-14
MX2007010889A (es) 2007-11-23
US20140112987A1 (en) 2014-04-24
RS20070365A (en) 2009-01-22

Similar Documents

Publication Publication Date Title
ME00199B (me) Gastrorezistentne farmaceutske formulacije koje sadrže rifaksimin
WO2007100902A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
CY1115082T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
DE60131703D1 (de) Orale feste pharmazeutische Zusammensetzungen zur pH-abhängig mehrphasigen Freisetzung
BR112013010853A2 (pt) "agentes citotóxicos compreendendo derivados de ansamitocina, composição farmacêutica e uso destes"
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
WO2011116139A3 (en) Improved pharmaceutical compositions comprising cck- 8 and methods of delivery
TW200806289A (en) Sustained-release formulation of zonisamide
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
WO2004041195A3 (en) Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
CY1112831T1 (el) Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
MX2009011316A (es) Derivados del acido lipoico.
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
UY28922A1 (es) Ligandos del receptor cb1 útiles en el tratamiento de dolor y/u otros síntomas o enfermedades relacionadas; compuestos farmacéuticos y su preparación.
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF